Viking Therapeutics, Inc. (VKTX)
Largest Insider Buys in Sector
VKTX Stock Price History Chart
VKTX Stock Performance
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in …
Insider Activity of Viking Therapeutics, Inc.
Over the last 12 months, insiders at Viking Therapeutics, Inc. have bought $0 and sold $87.42M worth of Viking Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Viking Therapeutics, Inc. have bought $224,995 and sold $37.11M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 90,000 shares for transaction amount of $222,390 was made by FOEHR MATTHEW W () on 2022‑05‑02.
List of Insider Buy and Sell Transactions, Viking Therapeutics, Inc.
| 2024-11-08 | Sale | director | 2,000 0.0018% | $68.67 | $137,333 | -25.50% | ||
| 2024-10-28 | Sale | Chief Financial Officer | 131,687 0.1468% | $76.61 | $10.09M | -4.26% | ||
| 2024-10-25 | Sale | director | 16,000 0.0185% | $79.50 | $1.27M | 0.00% | ||
| 2024-10-25 | Sale | director | 11,000 0.0129% | $80.89 | $889,790 | 0.00% | ||
| 2024-09-20 | Sale | President & CEO | 216,130 0.1961% | $70.83 | $15.31M | -11.70% | ||
| 2024-09-20 | Sale | director | 10,300 0.0092% | $69.50 | $715,850 | -11.70% | ||
| 2024-08-21 | Sale | President & CEO | 1,000 0.001% | $69.90 | $69,900 | -3.27% | ||
| 2024-08-21 | Sale | director | 5,700 0.0055% | $69.72 | $397,430 | -3.27% | ||
| 2024-08-19 | Sale | President & CEO | 112,870 0.1006% | $65.80 | $7.43M | -5.85% | ||
| 2024-08-19 | Sale | director | 16,000 0.0135% | $62.22 | $995,453 | -5.85% | ||
| 2024-08-14 | Sale | director | 20,786 0.0186% | $57.53 | $1.2M | 0.00% | ||
| 2024-07-30 | Sale | President & CEO | 115,859 0.1065% | $57.58 | $6.67M | -5.08% | ||
| 2024-07-30 | Sale | Chief Operating Officer | 18,026 0.0164% | $57.13 | $1.03M | -4.35% | ||
| 2024-07-30 | Sale | Chief Financial Officer | 16,136 0.0147% | $57.15 | $922,212 | -4.38% | ||
| 2024-05-03 | Sale | Chief Financial Officer | 66,756 0.0587% | $74.69 | $4.99M | -19.93% | ||
| 2024-05-01 | Sale | Chief Operating Officer | 281,425 0.2627% | $78.66 | $22.14M | -19.24% | ||
| 2024-02-09 | Sale | President & CEO | 45,000 0.0564% | $29.90 | $1.35M | +107.46% | ||
| 2024-02-08 | Sale | President & CEO | 269,079 0.3033% | $26.87 | $7.23M | +119.56% | ||
| 2024-02-08 | Sale | director | 25,000 0.0294% | $28.05 | $701,250 | +119.56% | ||
| 2024-01-31 | Sale | President & CEO | 85,000 0.0881% | $24.71 | $2.1M | +161.91% |
Insider Historical Profitability
| MACARTNEY LAWSON | director | 47965 0.043% | $42.25 | 1 | 4 | +92.12% |
| SINGLETON J MATTHEW | director | 9500 0.0085% | $42.25 | 1 | 5 | <0.0001% |
| FOEHR MATTHEW W | 111250 0.0998% | $42.25 | 5 | 1 | +1.66% | |
| Rowland Charles A Jr | director | 30000 0.0269% | $42.25 | 1 | 1 | +92.12% |
| Webster Stephen W | director | 8000 0.0072% | $42.25 | 1 | 0 | +92.12% |
Institutional Investor Ownership
| Fidelity Investments | $1.34B | 14.83 | 16.35M | +8.95% | +$110.12M | 0.09 | |
| BlackRock | $678.48M | 7.5 | 8.27M | +8.79% | +$54.8M | 0.02 | |
| The Vanguard Group | $638.43M | 7.06 | 7.79M | +44.66% | +$197.11M | 0.01 | |
| Avoro Capital Advisors Llc | $294.38M | 3.26 | 3.59M | New | +$294.38M | 3.53 | |
| State Street | $272.78M | 3.02 | 3.33M | -41.98% | -$197.33M | 0.01 |